Financials

  • Market Capitalization 260.97 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
4.03
Price to sales ratio
1.97

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3445
ALEC
Alector, Inc. - Common Stock
2.39 USD-2.85%+3.91%+58.28%0.00%266.86 M USD
3447
IVVD
Invivyd, Inc. - Common Stock
0.90 USD0.00%-5.26%+52.54%-14.29%265.28 M USD
3460
MGNX
MacroGenics, Inc. - Common Stock
4.08 USD+0.99%-0.24%+6.25%+137.21%259.90 M USD
3473
NAGE
Niagen Bioscience, Inc. - Common Stock
3.21 USD-2.73%+1.26%-1.83%-35.54%253.99 M USD

Frequently asked questions about Compugen Ltd

What is the Compugen Ltd stock price today?

The current price of Compugen Ltd (CGEN) is 2.76. Over the past 24 hours, the stock has changed by -2.82%. Follow the CGEN chart for real-time price dynamics.

What is the stock ticker of Compugen Ltd?

Compugen Ltd trades under the ticker CGEN. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Compugen Ltd stock going up?

CGEN has changed by +4.55% over the last week, +21.05% over the last month, and +97.14% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Compugen Ltd?

Compugen Ltd currently has a market capitalization of 260.97 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

How many employees does Compugen Ltd have?

As of the latest available data, Compugen Ltd has 75 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Compugen Ltd stock?

You can buy Compugen Ltd (CGEN) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Compugen Ltd stock?

Investing in Compugen Ltd requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CGEN chart and related analysis on metatrader.com as part of your research.

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

News